Skin testing with Mycobacterium avium sensitin (MAS) RS 10/2 and purified protein derivative (PPD) was conducted on patients with pulmonary disease due to M. avium complex (MAC) or Mycobacterium tuberculosis (MTB) and no known immunodeficiency. Reactions §5 mm to either MAS or PPD were present in 37 (84%) of 44 MAC patients and 28 (97%) of 29 MTB patients. MAC patients had a mean MAS reaction of 13.8 ({8.3) mm and a mean PPD reaction of 3.5 ({8.6) mm (P õ .001). MTB patients had a mean MAS reaction of 17.9 ({9.4) mm and a mean PPD reaction of 22.9 ({11.4) mm (P õ .001). MAS-dominant skin tests (MAS reaction §5 mm larger than PPD reaction) were present in 32 (73%) of 44 MAC patients and 1 (3%) of 29 MTB patients. MASdominant skin tests had a specificity of 97% for discriminating MAC disease from MTB disease.
Pulmonary disease due to organisms of the Mycobacterium the infection is due to MAC. Patient contacts may also be mismanaged. A more rapid and specific method for the diagnoavium complex (MAC) has been increasing over the past 20 years in the United States at a time when disease due to Mycosis of MAC disease is needed. Dual skin testing with purified protein derivative (PPD) from bacterium tuberculosis (MTB) has been decreasing [1, 2] . Because MAC disease is not reportable, the incidences of MAC MTB and purified proteins derived from MAC has been investigated as a method to discriminate disease due to MAC from and MTB cannot be compared. However, recent studies from several individual medical centers document higher rates of that due to MTB and might also be used to identify falsepositive PPD reactions due to prior MAC infection in healthy MAC disease than MTB disease in both the northern and southern United States [1, 3 -6] . Pulmonary MAC and pulmonary subjects [8] . Earlier studies in the United States demonstrated that dual skin testing with PPD and a MAC skin test reagent MTB disease may have similar clinical presentations, and acidfast bacilli may be demonstrated in sputum or bronchoalveolar designated PPD-B could distinguish MAC disease from MTB disease [9] , but this reagent is not currently available. In a lavage specimens in both diseases. Because isolation requirements and drug treatment differ for the two diseases, prompt recent unblinded study, we demonstrated that dual skin testing with PPD and a MAC skin test reagent designated M. avium distinction is important. When available, nucleic acid amplification techniques allow direct diagnosis of MTB from sputum sensitin (MAS) could distinguish patients with MAC disease from those with MTB disease [10] . Patients with MAC disease specimens in some cases [7] . However, direct and rapid tests to specifically identify MAC in respiratory tract specimens are had larger MAS skin test reactions than PPD skin test reactions, a pattern that was defined as an MAS-dominant skin test. We not available. Consequently, patients with MAC may be isolated inappropriately and have optimal antimicrobial treatment now present data demonstrating the potency and specificity of the MAS reagent in animals and data from a multicenter for MAC delayed several weeks until culture results reveal that blinded study in humans demonstrating the ability of dual skin testing with PPD and MAS to distinguish MAC pulmonary disease from MTB pulmonary disease.
Guinea pigs were immunized with four 0. disease by 1 of us.
An MAS-dominant skin test was defined as an MAS reaction of Characteristics for patients with MTB disease are listed in §5 mm that was also §5 mm larger than the PPD reaction. A table 2. Among MTB patients, 1 was entered from Dartmouth, PPD-dominant skin test was defined as a PPD reaction of §5 mm 22 from Grady, and 6 from Hennepin County Medical Center.
that was also §5 mm larger than the MAS reaction.
Their average age was 47 years; 21 were male; 3 were white, Results 24 were black, 1 was Native American, and 1 was Asian; 27 were born in the United States, and none had a history of BCG Animal studies. The log dose-response curve for MAS 10/ 2 in outbred guinea pigs was linear (figure 1). Specificity studimmunization. Two MTB patients (patients 15 and 17) had §2
/ 9d41$$mr15 01-07-98 00:23:11 jinfa UC: J Infect prior sputum cultures positive for MAC; both responded to MAS-dominant skin tests (positive mycobacterial skin test standard 4-drug therapy for tuberculosis.
and MAS reaction §5 mm larger than PPD reaction) were Mean skin test reactions and test characteristics for the 2 present in 32 (73%) of 44 patients with MAC disease and 1 patient groups are given in table 3 and are shown in figure 3 .
(3%) of 29 patients with MTB disease. MAS-dominant skin Positive mycobacterial skin tests ( §5-mm reaction to either tests had a specificity of 97% for discriminating pulmonary MAS or PPD) were present in 37 (84%) of 44 patients with MAC disease from pulmonary MTB disease. Two (5%) of 44 MAC and 28 (97%) of 29 patients with MTB. Patients with MAC patients had PPD reactions larger than MAS reactions: MAC had a larger mean MAS than mean PPD reaction. Patients MAC patient 2 was a 55-year-old man with close exposure to with MTB had a larger mean PPD than mean MAS reaction. tuberculosis 30 years earlier; MAC patient 38 was an 80-yearAmong patients with MTB, the mean MAS reaction was 19.1 old man with no known history of tuberculosis. One MTB mm for the 22 patients from Atlanta and 13.7 mm for 7 patients patient (patient 17) had an MAS-dominant skin test reaction; from the other two study sites (P Å .18); the mean PPD reaction this patient was 1 of 2 patients with §2 prior sputum cultures was 22.7 mm for the 22 patients from Atlanta and 23.4 mm also positive for MAC. PPD-dominant skin tests were present for 7 patients from the other two study sites (P Å .89). MTB in 15 (52%) of 29 patients with MTB disease and 2 (5%) of patients from Dartmouth and Mayo Clinic had a mean differ-44 patients with MAC disease. ence in MAS and PPD reactions of 7.9 mm, and MTB patients In total, 41 patients (21 MAC, 20 MTB) had MAS skin test from Atlanta had a mean difference in MAS and PPD reactions reactions §15 mm; blistering occurred in 2 patients, whose of 3.5 mm (P Å .02).
MAS/PPD reactions were 25/45 mm (MAC patient 2) and 50/ Negative mycobacterial skin tests (õ5-mm reaction to both 67 mm (MTB patient 20). All local reactions resolved sponta-MAS and PPD) were present in 7 (16%) of 44 patients with neously. Skin tests were performed with both MAS 10/1 and MAC and 1 (3%) of 29 patients with MTB. The 7 mycobacte-MAS 10/2 in 35 patients with MAC and 22 patients with MTB. rial skin test -negative MAC patients were all female, with an MAC patients had mean reaction sizes as follows: MAS 10/1 average age of 67; the 37 mycobacterial skin test -positive Å 10.1 mm; MAS 10/2 Å 14.0 mm. MTB patients had mean patients comprised 30 women and 7 men, with an average age reaction sizes as follows: MAS 10/1 Å 13.4 mm; MAS 10/2 of 72. All 7 women with negative mycobacterial skin tests Å 18.0 mm. were considered to have MAC disease and were treated for Discussion that; 6 had §2 sputum samples positive for MAC. Five of the Recent advances in the diagnosis and treatment of myco-7 mycobacterial skin test -negative female patients were tested with control antigens and none were anergic.
bacterial pulmonary disease have focused principally on / 9d41$$mr15 01-07-98 00:23:11 jinfa UC: J Infect MAC. This result may have been due to dual mycobacterial The definition of an MAS-dominant skin test could be set to be more sensitive for the identification of MAC disease (e.g., infection, microbiology laboratory error, an error in labeling blinded skin tests, or an actual biologic cross-reaction. The a 3-mm-dominant reaction in the present study would have a sensitivity of 77% compared with 73% for a 5-mm-dominant specificity of 97% in patients without known immunodeficiency is similar to the specificity of nucleic acid amplification reaction), but this would result in lower specificity (a 3-mmdominant reaction in the present study would have a specificity techniques used to confirm MTB [7] . Nucleic acid amplification techniques would be expected to be more sensitive than skin of 93% compared with 97% for a 5-mm-dominant reaction) and unacceptable misclassification of some cases of MTB distesting in immunodeficient patients. / 9d41$$mr15 01-07-98 00:23:11 jinfa UC: J Infect ease as MAC disease. Further, the reliability of detecting a preparation of PPD-B with a protein content of 0.1 mg/mL provided specificity in dual skin testing [9] but a preparation 3-mm difference between the two skin tests would be lower than for detecting a 5-mm difference. Clearly, dual skin tests with a protein content of 0.9 mg/mL did not [23] . In addition, local reactions were common with the high-protein-content rewith MAS 10/2 and PPD differing by õ3 mm would not provide acceptable discrimination between MAC disease and agent [24] . These reports are consistent with our findings, that higher doses of antigen produce larger reactions ( figure 1 ) and MTB disease. Considerable intra-and interobserver variability has been described in reading single skin tests [19] . However, that larger reactions reduce specificity and produce less discrimination in dual skin testing (figure 2). we would predict that the reliability of dual skin test reading would be higher, since this method does not depend on the Diagnostic skin testing for mycobacterial disease should be applied only to groups in which the tests have been evaluated. reader's ability to measure accurately an absolute skin test size, but rather on his or her ability to distinguish a relative differFor example, MAS skin testing might also have diagnostic utility in children with mycobacterial lymphadenitis, in which ence between two skin test sizes (i.e., a 5-mm-dominant reaction).
MAC is the most common pathogen [25] , but additional data need to be generated among children with this disease [26] . The sensitivity of dual skin testing for MAC disease is limited by the absence of skin test reactivity in some patients with Significantly, the present study was conducted among adult MAC pulmonary disease patients, most of whom were born in this disease. In our previous study, we found that some MAC patients older than 70 or with cachexia were anergic [10] . In the United States and had not received BCG. Further, MAC patients had no known history of tuberculosis (which may be the present study, we identified a subset of female patients who were unreactive to either mycobacterial skin test but were a predisposing factor for MAC pulmonary disease [27]), although the 2 MAC patients with large PPD reactions both had reactive to control skin tests. Defects in interferon-g function have been identified in patients with disseminated mycobactefeatures that raised the possibility of unrecognized prior MTB infection (age ú80, close exposure to MTB). Patients with rial infection [20] , and our finding suggests that some patients with localized MAC pulmonary disease may also have selective pulmonary disease due to Mycobacterium kansasii were not tested; therefore dual skin testing with the present reagents defects in delayed-type hypersensitivity reactions to mycobacteria.
could not be applied to patients with pulmonary mycobacterial disease in areas of the central United States where M. kansasii The present study was not designed to test the utility of a PPD-dominant skin test for the diagnosis of MTB disease.
is endemic [28] . The diagnosis of pulmonary disease due to MAC has been However, data on this definition are presented for comparison to a previous study with MAS 10/1, in which we found that a based on criteria developed by the American Thoracic Society: a compatible clinical syndrome without an alternate explana-PPD-dominant skin test could discriminate MTB disease from MAC disease among patients in the northern United States tion and §2 respiratory tract specimens positive for MAC [15] . Recent studies have shown that other features, such as [10] . In the present study, most MTB patients were from the southern United States, where background rates of MAS skin cylindrical bronchiectasis on computed tomography, may assist in confirming the diagnosis [29] . The present study indicates test positivity are higher (von Reyn CF, unpublished data) [21] . Consequently, as shown in figure 2, most patients with MTB that diagnostic dual skin testing with MAS 10/2 and PPD offers an additional and specific diagnostic test for pulmonary disease disease had PPD and MAS skin tests that differed by õ5 mm, and therefore the concept of a PPD-dominant skin test lacks due to MAC. Patients with mycobacterial disease who have at least a 5-mm reaction to one of the two mycobacterial skin clinical utility with MAS 10/2.
PPDs may vary in potency [22] , and it is essential that the tests and an MAS reaction that exceeds the PPD reaction by §5 mm have a high likelihood of having disease due to MAC. potency and cross-reactivity of every master batch of skin test reagent be tested in both experimentally sensitized or infected
The sensitivity and specificity of dual skin testing are comparable to culture but have the potential to provide more rapid animals and the naturally infected human subjects for whom the skin test is intended to be used as a diagnostic test. As results and to result in earlier institution of appropriate therapy directed at MAC, rather than MTB. shown here, animal tests must demonstrate equivalent potency but do not ensure that potency will be equivalent in humans. We found that MAS 10/2 was more potent than MAS 10/1 in humans, but an MAS-dominant skin test still provided excellent
